Response to the Letter by Spurling and Colleagues

Crit Care. 2023 Feb 20;27(1):65. doi: 10.1186/s13054-023-04352-6.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Humans
  • Propensity Score
  • Rivaroxaban*

Substances

  • prothrombin complex concentrates
  • PRT064445
  • apixaban
  • Rivaroxaban